An adamantamine derivative as a drug candidate for the treatment of visceral leishmaniasis
2021
Pomel, Sébastien | Cojean, Sandrine | Pons, Valérie | Cintrat, Jean-Christophe | Nguyen, Anvi Laetitia | Vacus, Joël | Pruvost, Alain | Barbier, Julien | Gillet, Daniel | Loiseau, Philippe | MetaboHUB-IDF | Commissariat à l'énergie atomique et aux énergies alternatives -MetaboHUB-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement | Service de Pharmacologie et Immunoanalyse | Médicaments et Technologies pour la Santé | Université Paris-Saclay-Direction de Recherche Fondamentale | Commissariat à l'énergie atomique et aux énergies alternatives -Commissariat à l'énergie atomique et aux énergies alternatives -Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement -Université Paris-Saclay-Direction de Recherche Fondamentale | Commissariat à l'énergie atomique et aux énergies alternatives -Commissariat à l'énergie atomique et aux énergies alternatives -Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement | Service d'Ingénierie Moléculaire pour la Santé
International audience
Show more [+] Less [-]English. Abstract Background This study aimed to investigate compounds acting on the host cell machinery to impair parasite installation with the possible advantage of limiting drug resistance. The strategy therefore consisted of selecting compounds that are poorly active on the axenic parasite, but very active on the intramacrophage form of Leishmania. Objectives To identify a drug candidate from focused screening of adamantamine derivatives that can inhibit the development of Leishmania infantum in macrophages. Methods In vitro screening was performed on a library of 142 adamantamine derivatives with axenic and intramacrophage forms of L. infantum, as well as cytotoxicity assays, allowing selection of the most promising compound. Absorption, distribution, metabolism and excretion (ADME) experiments, including pharmacokinetics and microsomal stability, were performed and finally the physicochemical stability of the compound was investigated to assess its suitability for further drug development. Results VP343 was identified first in vitro, with a CC50 value of 63.7 μM and an IC50 value of 0.32 μM for L. infantum intramacrophage amastigotes and then in vivo, with a 59% reduction of the liver parasite burden after oral administration at 10 mg/kg/day for 5 days. In addition, the ADME data were compatible with moving this compound further through the antileishmanial drug candidate pipeline. Conclusions VP343 has the properties of a good drug candidate and merits further investigations.
Show more [+] Less [-]Bibliographic information
This bibliographic record has been provided by National Institute for Agricultural Research